Translational Research Laboratory Prof CA Hart (IMIP), Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
Hospital de Câncer de Pernambuco, Recife, Brazil.
J Surg Oncol. 2024 Sep;130(4):734-740. doi: 10.1002/jso.27726. Epub 2024 Jun 10.
Previous studies have demonstrated that soluble forms of T-cell costimulatory molecules 4-1BB (s4-1BB) and OX40 (sOX40) interact with immune cells and may constitute a mechanism of immune evasion by tumors in various cancers. The role of the soluble forms of 4-1BB and OX40 in GC remains unclear. We aimed to examine the association between serum levels of s4-1BB and sOX40 and tumor progression in patients with GC.
Between 2017 and 2018, a cross-sectional study was performed with serum samples of 83 GC patients and 20 healthy controls.
Patients with stage IV metastatic gastric cancer had significantly higher levels of soluble OX40 in comparison with stage III patients with lymph nodes metastasis (p = 0.0003) and stages I and II patients (p = 0.005), whereas the opposite was found for soluble 4-1BB levels, with lower levels being found in advanced stage III (p = 0.003) compared with initial stages I/II.
The sOX40 and s4-1BB-mediated T cell interactions may be involved in antitumor immune responses in GC, possibly favoring tumor escape and progression. Serum levels of sOX40 and s4-1BB are associated with staging in GC and may constitute biomarkers for prognosis, as well as potential targets for immunotherapy.
先前的研究表明，T 细胞共刺激分子 4-1BB（s4-1BB）和 OX40（sOX40）的可溶性形式与免疫细胞相互作用，可能构成各种癌症中肿瘤免疫逃逸的一种机制。可溶性 4-1BB 和 OX40 形式在 GC 中的作用尚不清楚。我们旨在研究 GC 患者血清中 s4-1BB 和 sOX40 水平与肿瘤进展之间的关系。
2017 年至 2018 年，进行了一项横断面研究，纳入了 83 例 GC 患者和 20 名健康对照者的血清样本。
与淋巴结转移的 III 期患者（p=0.0003）和 I/II 期患者（p=0.005）相比，IV 期转移性胃癌患者的可溶性 OX40 水平显著更高，而可溶性 4-1BB 水平则相反，III 期晚期患者的水平较低（p=0.003）与初始 I/II 期相比。
sOX40 和 s4-1BB 介导的 T 细胞相互作用可能参与 GC 中的抗肿瘤免疫反应，可能有利于肿瘤逃避和进展。sOX40 和 s4-1BB 的血清水平与 GC 的分期相关，可能构成预后的生物标志物，以及免疫治疗的潜在靶点。
